Open AccessCD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection
Author(s) -
Suefen Kwa,
Shanmugalakshmi Sadagopal,
Xiaoying Shen,
Jung Joo Hong,
Sailaja Gangadhara,
Rahul Basu,
Blandine Victor,
Smita S. Iyer,
Celia C. LaBranche,
David C. Montefiori,
Georgia D. Tomaras,
François Villinger,
Bernard Moss,
Pamela A. Kozlowski,
Rama Rao Amara
Publication year - 2015
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.03527-14
Subject(s) - simian immunodeficiency virus , virology , biology , vaccinia , modified vaccinia ankara , virus , neutralization , gp41 , antibody , poxviridae , epitope , immunology , biochemistry , gene , recombinant dna
Here, we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances protection against a pathogenic neutralization-resistant mucosal SIV infection, improves long-term viral control, and prevents AIDS. Analyses of serum IgG antibodies to linear peptides of SIV Env revealed a strong response to V2, with targeting of fewer epitopes in the immunodominant region of gp41 (gp41-ID) and the V1 region as a correlate for enhanced protection. Greater expansion of antiviral CD8 T cells in the gut correlated with long-term viral control.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom